Healthy Competition: Valeant Pharmaceuticals Intl Inc. vs. Jamieson Wellness Inc.

Canadians are spending more money on healthcare products as the population ages, but investors need to choose carefully between companies such as Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Jamieson Wellness Inc. (TSX:JWEL).

| More on:
The Motley Fool

Health expenditures as a percentage of GDP passed the 10% mark in 2010, and with an aging population, it is projected to grow in the coming decades. Individual consumer spending has also increased over time and, as expected, shows a marked uptick with advanced age. In the United States, state and individual spending is even higher, and biotechnology stocks have been some of the best-performing stocks since the 2008 Financial Crisis.

Pharmaceuticals, supplements, and vitamin markets show no signs of slowing down. Today, we are going to take a look at two stocks in the Canadian market to determine which is better to target moving forward.

Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) is a Laval-based multinational that develops and manufactures pharmaceutical products across a broad range of categories. The company saw its stock price rise to impressive heights before a drug-price-hike controversy sunk the stock; it has retreated over 90% from its all-time highs. Now, the company is doing its best to claw back from a large debt hole.

Valeant released its second-quarter results on August 8. Revenue fell 8% to $2.23 billion from $2.42 billion in Q2 2016. The company reported a decline in volume and price in U.S. product segments and weakness in the dermatology business. Valeant was happy to project that it will be able to pay down $5 billion in debt before the February 2018 deadline. Operating income climbed to $175 million compared to $81 million in the second quarter of 2016. Adjusted EBITDA was down $136 million due to the weaknesses experienced in the past quarter.

Jamieson Wellness Inc. (TSX:JWEL) is a manufacturer and distributor of vitamin and health products. The company recently had its initial public offering on the Toronto Stock Exchange on July 7. Since the IPO, the stock has increased 8.5%. Jamieson has touted its long-term growth outlook on the basis that an aging population will drive business expansion. There is no doubt that the market for health supplements has exploded, as people look to live healthier and longer lives. Jamieson has hundreds of products in over 10,000 stores in Canada alone and is looking to expand into Asia, the Middle East, and eastern Europe.

Jamieson released its second-quarter results on August 9. Revenue experienced growth of 6.3% to $71.3 million. Adjusted EBITDA climbed 25% to $15.1 million and adjusted net income was reported at $7.9 million. Gross profit jumped 18.4% to $25.3 million compared to $21.4 million in Q2 2016. Jamieson still expects to see revenue in the range of $303-310 million in 2017.

Which should you buy?

Valeant continues to face big challenges in the shadow of the controversies that erupted in 2015. Jamieson is the better buy now and moving forward after a very solid second-quarter report. Pending third-quarter results that yield similar success, I could see Jamieson stock reach above the $20 mark before 2017 comes to an end.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Fool contributor Ambrose O'Callaghan has no position in any stocks mentioned.

More on Investing

A worker drinks out of a mug in an office.
Dividend Stocks

A Dividend Giant I’d Buy Over BCE Stock Right Now

The largest telecom company in Canada is brutally discounted, and the dividend yield is naturally up, but it's too risky…

Read more »

a man celebrates his good fortune with a disco ball and confetti
Dividend Stocks

Get Ready to Invest $7,000 in This Dividend Stock for New Year Passive Income

This is the year you get ahead, and maxing out your TFSA contribution is the best way to start.

Read more »

ways to boost income
Dividend Stocks

Buy 2,653 Shares of This Top Dividend Stock for $10K in Annual Passive Income

Enbridge is a blue-chip TSX dividend stock that offers shareholders a forward yield of 6%. Is it still a good…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, December 13

Down 1.1% week to date, the TSX Composite Index seems on track to end its five-week winning streak.

Read more »

ETF stands for Exchange Traded Fund
Bank Stocks

A Canadian Bank ETF I’d Buy With $1,000 and Hold Forever

This unique Hamilton ETF gives you 1.25x leveraged exposure to Canada's Big Six bank stocks.

Read more »

a person looks out a window into a cityscape
Dividend Stocks

1 Marvellous Canadian Dividend Stock Down 11% to Buy and Hold Immediately

Buying up this dividend stock while it's down isn't just a smart move, it could make you even more passive…

Read more »

Blocks conceptualizing the Registered Retirement Savings Plan
Dividend Stocks

CPP at 70: Is it Enough if Invested in an RRSP?

Even if you wait to take out CPP at 70, it's simply not going to cut it during retirement. Which…

Read more »

A shopper makes purchases from an online store.
Tech Stocks

The Smartest Growth Stock to Buy With $1,000 Right Now

Given its solid sales growth, improved profitability, and healthy growth prospects, Shopify would be an excellent buy.

Read more »